A real-world study on prevalence of and outcomes related to brain metastases among patients with HER2-positive metastatic breast cancer (mBC)

被引：0

作者：

Collins, J. ^{[1
]}

Varghese, D. ^{[2
]}

Miranda, M. ^{[3
]}

Nordstrom, B. ^{[4
]}

Murphy, B. ^{[5
]}

Harland, D. ^{[6
]}

机构：

[1] Evidera Waltham, Res, Waltham, MA USA

[2] AstraZeneca, Real World Evidence Generat & Epidemiol, Gaithersburg, MD USA

[3] AstraZeneca, Stat, Cambridge, England

[4] Evidera Waltham, Epidemol, Real World Evidence, Waltham, MA USA

[5] Evidera Waltham, Stat, Waltham, MA USA

[6] AstraZeneca, Global Med Affairs, Cambridge, England

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.03.205

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

186P

引用

页码：S213 / S213

页数：1

共 50 条

[21] Survival analysis of pyrotinib in HER2-positive metastatic breast cancer: A multicenter real-world study. [J].

Li, Shiyi ;

Xu, Ting ;

Zhu, Chengjun ;

Shan, Hx ;

Xu, Hong ;

Zhou, Jun ;

Yang, Lei ;

Yi, Tongbo ;

Wu, Xiaohong ;

Zhang, Yusong ;

Xie, Li ;

Yuan, Yuan ;

Zhang, Lili .

JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (16_SUPPL) :e13007-e13007

[22] Brain metastases in HER2-positive breast cancer [J].

Lin, Nancy U. .

LANCET ONCOLOGY, 2013, 14 (03) :185-186

[23] Clinical characteristics, treatment patterns, and outcomes for patients with HER2-positive metastatic breast cancer (MBC) treated with pertuzumab (P) in the first-line in a real-world setting [J].

Robert, N. ;

Goertz, H. P. ;

Asmar, L. ;

Tseng, W. Y. ;

Jiao, X. ;

Portera, C. ;

Yoo, B. ;

Patt, D. ;

Antao, V. .

EUROPEAN JOURNAL OF CANCER, 2015, 51 :S288-S288

[24] Screening of brain metastases in patients with HER2-positive breast cancer [J].

Kabashi, F. ;

Leser, C. ;

Singer, C. ;

Gschwantler-Kaulich, D. .

GEBURTSHILFE UND FRAUENHEILKUNDE, 2025, 85 (04) :E4-E4

[25] Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study [J].

Huang, Jie ;

Sun, Shujuan ;

Tan, Qiaorui ;

Zheng, Fangchao ;

Zhou, Dongdong ;

Man, Xiaochu ;

Hu, Yu ;

Li, Wenhuan ;

Song, Lihua ;

Zhang, Baoxuan ;

Xu, Liang ;

Wang, Xinzhao ;

Xie, Xuemei ;

Li, Huihui .

CLINICAL BREAST CANCER, 2024, 24 (06) :e509-e518.e1

[26] Systemic therapy and overall survival (OS) in patients (pts) with brain metastases from HER2-positive (HER2+) metastatic breast cancer (MBC). [J].

Bartsch, R. ;

Berghoff, A. ;

Pluschnig, U. ;

Bago-Horvath, Z. ;

Dubsky, P. C. ;

Rottenfusser, A. ;

Wenzel, C. ;

Rudas, M. ;

Fitzal, F. ;

Dieckmann, K. ;

Gnant, M. ;

Zielinski, C. ;

Steger, G. G. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)

[27] Real-world Outcomes of Dual HER2 Blockade Therapy in Metastatic HER2-Positive Breast Cancer: from Induction to Maintenance [J].

Krizic, Marija ;

Popovic, Marina ;

Silovski, Tajana ;

Grbin, Dorotea ;

Plavetic, Natalija Dedic .

DRUGS-REAL WORLD OUTCOMES, 2024, 11 (03) :413-423

[28] Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry [J].

Lux, Michael P. ;

Nabieva, Naiba ;

Hartkopf, Andreas D. ;

Huober, Jens ;

Volz, Bernhard ;

Taran, Florin-Andrei ;

Overkamp, Friedrich ;

Kolberg, Hans-Christian ;

Hadji, Peyman ;

Tesch, Hans ;

Haeberle, Lothar ;

Ettl, Johannes ;

Lueftner, Diana ;

Wallwiener, Markus ;

Mueller, Volkmar ;

Beckmann, Matthias W. ;

Belleville, Erik ;

Wimberger, Pauline ;

Hielscher, Carsten ;

Geberth, Matthias ;

Abenhardt, Wolfgang ;

Kurbacher, Christian ;

Wuerstlein, Rachel ;

Thomssen, Christoph ;

Untch, Michael ;

Fasching, Peter A. ;

Janni, Wolfgang ;

Fehm, Tanja N. ;

Wallwiener, Diethelm ;

Schneeweiss, Andreas ;

Brucker, Sara Y. .

CANCERS, 2019, 11 (01)

[29] Use and outcomes of trastuzumab deruxtecan in HER2-positive and HER2-low metastatic breast cancer in a real-world setting: a nationwide cohort study [J].

Jourdain, H. ;

Di Meglio, A. ;

Mansouri, I. ;

Desplas, D. ;

Zureik, M. ;

Haddy, N. .

ESMO OPEN, 2024, 9 (12)

[30] Use and Outcomes of Trastuzumab Deruxtecan in HER2-positive and HER2-low Metastatic Breast Cancer in Real-World Setting: A Nationwide Cohort Study [J].

Jourdain, Hugo ;

Desplas, David ;

Mansouri, Imene ;

Zureik, Mahmoud ;

Di Meglio, Antonio ;

Haddy, Nadia .

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2024, 33 :531-531

← 1 2 3 4 5 →